Pharvaris N.V. (PHVS) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 98.0% versus a gain of 36.2%. Over five years, PHVS leads with a +96.8% price change compared with -61.5% for PVLA. Pharvaris N.V. is the larger company by market cap ($2.18 billion vs $2.00 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | PVLA |
|---|---|---|
| Share price | $31.10 | $138.77 |
| Market cap | $2.18B | $2.00B |
| 1-day change | -0.06% | +5.66% |
| YTD return | +12.07% | +32.58% |
| 1-year return | +36.16% | +97.99% |
| 5-year return | +96.84% | -61.54% |
| EPS (TTM) | $-3.06 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-25.99M | $-41.72M |
| 52-week high | $43.25 | $161.38 |
| 52-week low | $20.65 | $66.58 |
| Distance from 52-week high | -28.09% | -14.01% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +84.47% | +66.12% |
| Average volume | 711.75K | 211.30K |
| Shares outstanding | 70.20M | 14.41M |
| Employees | 148 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed PHVS by 61.8 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Healthcare · Biotechnology · 148 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Healthcare · Biotechnology · 29 employees
PHVS vs PVLA FAQ
Which is bigger, Pharvaris N.V. or Palvella Therapeutics?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.18B compared with $2.00B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, PHVS or PVLA?
PVLA returned +97.99% over the past 12 months, compared with +36.16% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.